IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO
Rosh Pina, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform, which addresses significant healthcare needs, today published a poster presentation on its website titled “Near Infra-Red Spectroscopy scanner for early detection of stage 1 pressure injury and deep tissue injury – clinical study results”, which includes data that was presented at the National Pressure Injury Advisory Panel (NPIAP) 2024 Annual Conference in San Antonio, Texas. The poster was also recently shared by Clalit Innovation, which described PressureSafe™ as a “Breakthrough in pressure ulcer diagnosis…” and “Truly groundbreaking impact of an innovative tool!”.
- PressureSafe™ is a decision support device that has received U.S. Food and Drug Administration (FDA) listing confirmation for the indication of pressure injuries.
- IR-MED conducted a usability study in conjunction with two medical centers owned by Clalit, the world’s second largest health maintenance organization (HMO) and the largest HMO in Israel.
- During the study period, the incidences of pressure injuries were reduced by 50% in comparison to the levels prior to the study.
- Patient care costs per pressure injury ranges from $20,900 up to $151,700, for the 2.5 million patients per year who develop pressure injuries.